azoxymethane has been researched along with sulindac sulfone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahnen, DJ; Alberts, DS; Bogert, C; Brendel, K; Burt, RW; Ellsworth, L; Finn, T; Gross, PH; Guillen, JM; Hixson, LJ; Li, H; Pamukcu, R; Paranka, NS; Piazza, GA; Ritchie, J; Sperl, G | 1 |
| Kawamori, T; Kelloff, GJ; Lubet, RA; Rao, CV; Reddy, BS; Steele, VE | 1 |
2 other study(ies) available for azoxymethane and sulindac sulfone
| Article | Year |
|---|---|
Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels.
Topics: Animals; Anticarcinogenic Agents; Azoxymethane; Carcinogens; Colonic Neoplasms; Dinoprostone; Male; Rats; Rats, Inbred F344; Sulindac | 1997 |
Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process.
Topics: Adenocarcinoma; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Azoxymethane; Carcinogens; Cell Transformation, Neoplastic; Colonic Neoplasms; Cyclooxygenase Inhibitors; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Male; Neoplasm Invasiveness; Rats; Rats, Inbred F344; Sulindac; Weight Gain | 1999 |